Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of triple negative breast cancer metastasis and invasiveness by novel drugs that target epithelial to mesenchymal transition
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-03
DOI
10.1038/s41598-021-91344-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
- (2020) Sima Lev BIOCHEMICAL SOCIETY TRANSACTIONS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Trabedersen (AP 12009) in the treatment of patients with advanced tumors: Completion of dose-escalation and first efficacy data.
- (2017) H. Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab-Related Cardiac Dysfunction
- (2017) Melinda L. Telli et al. Journal of the National Comprehensive Cancer Network
- Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences
- (2016) S Chaurasiya et al. CANCER GENE THERAPY
- An overview of triple-negative breast cancer
- (2015) Pankaj Kumar et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a -Secretase Inhibitor
- (2015) K. Wang et al. CLINICAL CANCER RESEARCH
- Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance):
- (2014) WM Sikov et al. CANCER RESEARCH
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- OT3-01-11: A Randomized, Phase II Multicenter, Double-Blind, Placebo-Controlled Trial Evaluating MetMAb and/or Bevacizumab in Combination with Weekly Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer.
- (2012) BR Daniel et al. CANCER RESEARCH
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonism of miR-21 Reverses Epithelial-Mesenchymal Transition and Cancer Stem Cell Phenotype through AKT/ERK1/2 Inactivation by Targeting PTEN
- (2012) Mingli Han et al. PLoS One
- NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
- (2012) Foluso O. Ademuyiwa et al. PLoS One
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- The cardiac safety of trastuzumab in the treatment of breast cancer
- (2010) A Jo Chien et al. Expert Opinion On Drug Safety
- Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
- (2010) Daniel P. Silver et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
- (2009) Piyush B. Gupta et al. CELL
- BMP-6 inhibits microRNA-21 expression in breast cancer through repressing δEF1 and AP-1
- (2009) Jun Du et al. CELL RESEARCH
- Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise
- (2009) Karen Y. Wonders et al. INTEGRATIVE CANCER THERAPIES
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
- (2008) D. Sarrio et al. CANCER RESEARCH
- Triple-negative/basal-like breast cancer: review
- (2008) Emad A. Rakha et al. PATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now